Acute coronary syndromes (ACS) represent a major contributor to mortality, morbidity, and
healthcare costs. Effective therapies are widely available; however, adherence is low. This
contributes to worse patient outcomes and increased risk of morbidity and mortality. The
once-daily polypill leverages a population-based strategy that has previously demonstrated
efficacy in improving adherence and access to therapy in low-resource settings, making it an
innovative approach for improving post-ACS care. This study aims to investigate the utility
of a polypill-based strategy for patients with ACS with drug eluting stent (DES) placement.
The polypill will consist of a high-intensity statin (rosuvastatin 40 mg daily), aspirin 81
mg daily, and prasugrel 10 mg daily.